60 Degrees Pharmaceuticals (SXTP) EPS (Weighted Average and Diluted) (2022 - 2025)
Historic EPS (Weighted Average and Diluted) for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$0.66.
- 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) rose 7739.73% to -$0.66 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.28, marking a year-over-year increase of 9962.57%. This contributed to the annual value of -$18.55 for FY2024, which is 6866.32% up from last year.
- According to the latest figures from Q3 2025, 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) is -$0.66, which was up 7739.73% from -$1.18 recorded in Q2 2025.
- In the past 5 years, 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $9.13 in Q3 2023 and a low of -$31.32 during Q4 2023
- Over the past 4 years, 60 Degrees Pharmaceuticals' median EPS (Weighted Average and Diluted) value was -$1.15 (recorded in 2023), while the average stood at -$5.2.
- The largest annual percentage gain for 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) in the last 5 years was 159888.14% (2023), contrasted with its biggest fall of 437647.05% (2023).
- 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.7 in 2022, then tumbled by 4376.47% to -$31.32 in 2023, then skyrocketed by 84.69% to -$4.8 in 2024, then surged by 86.24% to -$0.66 in 2025.
- Its last three reported values are -$0.66 in Q3 2025, -$1.18 for Q2 2025, and -$1.56 during Q1 2025.